IL134593A0 - A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof - Google Patents

A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof

Info

Publication number
IL134593A0
IL134593A0 IL13459398A IL13459398A IL134593A0 IL 134593 A0 IL134593 A0 IL 134593A0 IL 13459398 A IL13459398 A IL 13459398A IL 13459398 A IL13459398 A IL 13459398A IL 134593 A0 IL134593 A0 IL 134593A0
Authority
IL
Israel
Prior art keywords
methods
pharmaceutical compositions
preparation
cell system
same
Prior art date
Application number
IL13459398A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL134593A0 publication Critical patent/IL134593A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13459398A 1997-08-29 1998-08-25 A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof IL134593A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (1)

Publication Number Publication Date
IL134593A0 true IL134593A0 (en) 2001-04-30

Family

ID=22009467

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13459398A IL134593A0 (en) 1997-08-29 1998-08-25 A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof
IL134593A IL134593A (en) 1997-08-29 2000-02-17 Pharmaceutical preparations containing a gene encoding interferon-beta protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL134593A IL134593A (en) 1997-08-29 2000-02-17 Pharmaceutical preparations containing a gene encoding interferon-beta protein

Country Status (24)

Country Link
EP (1) EP1007717B8 (cs)
JP (3) JP4124565B2 (cs)
KR (1) KR100699285B1 (cs)
CN (1) CN100342019C (cs)
AT (1) ATE316145T1 (cs)
AU (1) AU740428B2 (cs)
BR (1) BR9812138A (cs)
CA (1) CA2300480C (cs)
CY (1) CY1105029T1 (cs)
CZ (2) CZ299095B6 (cs)
DE (1) DE69833264T2 (cs)
DK (1) DK1007717T3 (cs)
EA (1) EA003256B1 (cs)
EE (1) EE04873B1 (cs)
ES (1) ES2257817T3 (cs)
HU (1) HU224422B1 (cs)
IL (2) IL134593A0 (cs)
IS (1) IS2318B (cs)
NO (1) NO20000990L (cs)
NZ (1) NZ503401A (cs)
PT (1) PT1007717E (cs)
SK (1) SK286821B6 (cs)
TR (1) TR200000532T2 (cs)
WO (1) WO1999010516A2 (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219142T2 (de) * 2001-01-22 2007-12-13 Biogen Idec Ma Inc., Cambridge Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
US20220364122A1 (en) * 2019-06-01 2022-11-17 Sivec Biotechnologies Llc Bacterial platform for delivery of gene-editing systems to eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
AU711269B2 (en) * 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
IL134593A (en) 2007-06-17
EE04873B1 (et) 2007-08-15
EP1007717A2 (en) 2000-06-14
SK2482000A3 (en) 2000-08-14
EP1007717B1 (en) 2006-01-18
PT1007717E (pt) 2006-06-30
HUP0002913A2 (hu) 2000-12-28
EP1007717B8 (en) 2006-05-03
AU740428B2 (en) 2001-11-01
HK1029599A1 (en) 2001-04-06
CZ2000733A3 (cs) 2000-06-14
ATE316145T1 (de) 2006-02-15
CA2300480C (en) 2010-01-05
DE69833264D1 (de) 2006-04-06
BR9812138A (pt) 2000-07-18
NZ503401A (en) 2003-01-31
IS5374A (is) 2000-02-11
WO1999010516A2 (en) 1999-03-04
JP2001514010A (ja) 2001-09-11
KR20010023511A (ko) 2001-03-26
ES2257817T3 (es) 2006-08-01
EA003256B1 (ru) 2003-02-27
JP2004155786A (ja) 2004-06-03
NO20000990D0 (no) 2000-02-28
JP4219335B2 (ja) 2009-02-04
TR200000532T2 (tr) 2000-11-21
SK286821B6 (sk) 2009-06-05
JP4124565B2 (ja) 2008-07-23
NO20000990L (no) 2000-05-02
EE200000102A (et) 2000-12-15
JP2005225888A (ja) 2005-08-25
HUP0002913A3 (en) 2003-08-28
CZ297314B6 (cs) 2006-11-15
KR100699285B1 (ko) 2007-03-26
CA2300480A1 (en) 1999-03-04
AU9205198A (en) 1999-03-16
CN100342019C (zh) 2007-10-10
CY1105029T1 (el) 2010-03-03
IS2318B (is) 2007-11-15
DK1007717T3 (da) 2006-05-29
EA200000270A1 (ru) 2000-10-30
JP3953458B2 (ja) 2007-08-08
WO1999010516A3 (en) 1999-05-06
CN1271391A (zh) 2000-10-25
CZ299095B6 (cs) 2008-04-23
HU224422B1 (hu) 2005-08-29
DE69833264T2 (de) 2006-09-28

Similar Documents

Publication Publication Date Title
EP1024197A3 (en) Mesothelial cell gene therapy
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
FI930883A7 (fi) Aktiivisten tekijöiden in vivo -annostelu keraviljeltyjen solusiirränn äisten avulla
ES2149774T3 (es) Aportacion dirigida de genes que codifican proteinas secretoras.
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
WO1999032516A3 (en) Pharmaceutical compositions containing the long pentraxin ptx3
EP1007717B8 (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
DE69725754D1 (de) Eingekapselte Antikörper-produzierende Zellen
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
EP0452894A3 (en) Human cells for the high expression of genes inserted in episomal recombinant dna, their preparation and their use
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO2000006735A8 (en) Interferon alpha hybrids
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed